Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromosome 9 open reading frame 72 (C9orf72) is a gene whose hexanucleotide (GGGGCC) repeat expansion in the first intron is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (DeJesus-Hernandez et al., 2011; Renton et al., 2011). The C9orf72 protein functions as a guanine nucleotide exchange factor (GEF) for Rab GTPases, playing a critical role in endosomal trafficking, autophagy, and lysosomal function (Sellier et al., 2016; UniProt Q96LT7). In disease states, the expansion leads to three primary pathogenic mechanisms: loss of C9orf72 protein function (haploinsufficiency), toxic gain-of-function from RNA foci, and the production of toxic dipeptide repeat (DPR) proteins through non-canonical translation (Taylor et al., 2016). Therapeutic strategies primarily focus on using antisense oligonucleotides (ASOs) or gene therapy to selectively reduce the levels of expansion-containing transcripts while preserving the expression of the wild-type allele (Lagier-Tourenne et al., 2013). Despite several high-profile clinical trial failures, such as BIIB078 and WVE-004, C9orf72 remains a high-priority target for neurodegenerative disease modification (Biogen, 2022; Wave Life Sciences, 2023).
Antisense-mediated degradation of hexanucleotide repeat-containing RNA transcripts to reduce toxic gain-of-function from RNA foci and dipeptide repeat protein production (Lagier-Tourenne et al., 2013; Smith et al., 2017).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromosome 9 open reading frame 72 (C9orf72) (C9orf72).